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Although macrophage migration inhibitory factor (MIF) has consistently been shown to 
be an important immune modulator, data on the association between MIF promoter 
variations and the risk of developing rheumatic heart disease (RHD) remain inconclusive. 
RHD is an important complication of streptococcal infections in the Middle East, not 
least in Saudi Arabia, and identifying risk markers is an important priority. Therefore, we 
investigated the association between two functional MIF promoter variations and RHD 
susceptibility and severity in Saudi patients: the MIF-173G > C substitution (rs755622) 
and the MIF-794 CATT5–8 tetranucleotide repeat (rs5844572). Three hundred twenty-six 
individuals (124 RHD patients and 202 age-, sex-, and ethnically matched healthy 
controls) were genotyped using allelic discrimination and fragment analysis. Data were 
analyzed with respect to disease susceptibility, severity, sex, and age of onset. There 
was a significantly lower frequency of 173C allele carriage in RHD patients compared to 
controls [odds ratio (OR) = 0.47; 95% confidence intervals (CIs) = 0.28–0.77; p = 0.003]. 
Interestingly, the 173C allele was associated with late disease onset (p = 0.001). The 794 
5-repeat allele was associated with decreased RHD risk (OR = 0.56; 95% CIs = 0.38–
0.82; p = 0.003). In contrast, the 794 6-repeat allele was associated with increased risk 
of RHD (OR = 1.7; 95% CIs = 1.2–2.5; p = 0.002). MIF promoter variations appear to 
have a dual role in RHD, with 173C allele non-carriers at higher risk of developing RHD at 
a younger age. These results require further validation in larger multi-ethnic cohorts, and 
functional studies are necessary to understand the underlying molecular mechanisms 
driving the at-risk phenotype.
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inTrODUcTiOn
Rheumatic heart disease (RHD) is an autoimmune disease that can develop following throat 
infections with one of the group A beta-hemolytic streptococci (GAS). Although standard antibi-
otic treatments are effective and help to prevent the disease, RHD is a common source of acquired 
pediatric heart disease in many developing nations (1), to the extent that the World Health 
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Organization (WHO) (2) and World Heart Federation (WHF) 
(3) recognize RHD as a neglected tropical disease (NTD). It is 
estimated that GAS infection is a major global human pathogen 
that causes morbidity and mortality only exceeded by HIV, TB, 
and malaria (4). RHD is also an important and ongoing cause of 
cardiac disease in indigenous populations in developed coun-
tries (5, 6). For example, in a hospital-based study of children 
admitted with rheumatic fever (RF), the precursor of RHD, in 
Saudi Arabia, carditis was reported in 53% and severe carditis in 
32% of cases (7). RF was more common in children from urban, 
low-income, and densely populated areas. In another study in 
western Saudi Arabia, Al-Sekait et al. assessed the prevalence 
of RHD in 9418 school children aged between 6 and 15 years 
(8) (representing 10% of the target population) and showed 
that RHD prevalence was 2.4/1000 (8). Molecular mimicry is 
thought to trigger RHD (9); however, the exact mechanisms 
underlying autoimmunity and cardiac tissue damage remain 
unknown.
Of note, only some GAS strains are rheumatogenic (10), and 
only 50% of individuals infected with these strains develop RHD 
(9). Furthermore, the disease appears to have a familial compo-
nent: familial predisposition in RF was reported as early as 1889 
by Cheadle, who estimated a five times greater risk of develop-
ing the disease in individuals with a family history compared 
to those without a family history (11). A meta-analysis of twin 
studies estimated that 60% of RF risk was heritable (12), which is 
higher than some other well-characterized complex autoimmune 
diseases (13). These data highlight the importance of a genetic 
component to the disease, and genetic variability in inflammatory 
and immune genes has been associated with RHD development 
and severity (10, 14–16).
Macrophage migration inhibitory factor (MIF) is a pleiotropic 
immune mediator important in innate and adaptive immune 
responses. MIF is a small gene (<0.7 kb) of three exons located 
on 22q11.2, and it is highly conserved across different species 
(17). MIF expression is rapidly induced by low concentrations 
of Gram-positive staphylococcal and streptococcal components 
(18), resulting in the production of a variety of cells types includ-
ing macrophages, lymphocytes, and epithelial cells. MIF exerts 
a wide range of proinflammatory activities by upregulating 
expression of a variety of immune mediators including TLR4, 
IL-6, and TNFα (17, 19) and overriding the immunosuppressive 
activity of glucocorticoids (17). Studies on infarcted myocardium 
have shown opposing actions for MIF depending on disease stage 
and its cellular source (20). For example, MIF is cardioprotec-
tive when cardiac ischemia/reperfusion is brief (21), but when 
ischemia is prolonged, MIF activates immune cells and increases 
inflammation (22).
The MIF promoter contains two functional variations that 
affect its gene expression and protein levels in vitro and in vivo: a 
MIF-173G > C substitution (rs755622) and a MIF-794 CATT5–8 
tetranucleotide repeat (rs5844572) (23, 24). The C allele at the 173 
position is associated with higher MIF expression in T cell lines; 
however, in a lung carcinoma cell line, the G allele was associated 
with higher gene expression (25). In vitro and in vivo studies have 
shown that a greater number of CATT repeats are associated with 
higher gene expression (17, 24).
Migration inhibitory factor is pathogenic in several diseases 
including infectious (26), autoimmune (17), and cardiovascular 
diseases (20). In infectious diseases, MIF promotes pneumococcal 
clearance (26); however, MIF alleles that promote gene expression 
are associated with severe malarial anemia (27). MIF plays a dual 
role in autoimmune diseases; for example, alleles that promote 
gene expression protect against systemic lupus erythematosus 
(SLE) but, in patients with established disease, alleles that reduce 
expression protect against disease complications and multiple 
organ involvement (28). Studies on the genetic factors that 
contribute to RHD risk and severity are scarce, especially in the 
developed world. Therefore, we tested the hypothesis that MIF 
promoter variations modulate the course of RHD by evaluating 
these sequence variants in relation to RHD susceptibility, severity, 
and age of onset in 326 Saudi Arabian participants.
MaTerials anD MeThODs
study Population
One hundred and twenty-four RHD patients were enrolled in a 
pilot study at the Pediatric Cardiology Clinic at the Maternity and 
Children Hospital, Al-Madinah region, Saudi Arabia between 
March 2013 and June 2014. The Maternity and Children Hospital 
ethics committee approved the study protocol, and the authors 
followed the norms of the World Medical Association Declaration 
of Helsinki. All adult patients and donors or the parents or guard-
ians of child participants (<18 years old) signed a fully informed 
and written consent form approved by the ethics committee.
The patient and control cohorts are described in previous 
studies (15, 16). Briefly, diagnosis was made according to the 
modified Jones criteria at initial diagnosis and confirmed by 
echocardiography (29). Patients were subgrouped according to 
echocardiographic findings into either mitral valve lesion (MVL) 
or multiple valve lesions including the mitral valve, termed a 
“combined valve lesion” (CVL). Exclusion criteria were patients 
with RF but without valvular disease, heart complications, or other 
inflammatory conditions. Age of onset was the age at which the 
patient had his/her first diagnosis confirmed by echocardiogra-
phy. The control group was a random population sample of 202 
healthy volunteers identified via the National Blood Service in the 
Al-Madinah region. Controls were age-, gender-, and ethnically 
matched unrelated volunteers with no history of cardiac or auto-
immune diseases. All participants were of Saudi Arabian ethnicity.
genotyping MiF Promoter Polymorphisms
DNA was purified from 2-ml whole blood using the QIAamp 
DNA Mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. Extracted DNA was quantified by 
spectrophotometry (MaestroNano, MaestroGen, Las Vegas, NV, 
USA) and stored at −20°C until use. The MIF-173 polymor-
phism was genotyped using the duplex quantitative TaqMan 
5′ Allelic Discrimination Assay (Applied Biosystems, Foster 
City, CA, USA; assay ID C_2213785_10) as directed by the 
manufacturer. Briefly, assays were performed in a final volume 
of 10 μl (including TaqMan Genotyping Master Mix, 40× SNP 
Genotyping Assay Mix, DNase-free water, and 20-ng DNA) in 
96-well plates using the following amplification protocol: 95°C 
TaBle 1 | Demographic characteristics and clinical details of the 
patients (n = 124) and controls (n = 202).
Parameter Value
average age (mean ± sD years)
Controls 20.5 ± 4.2
Patients (at follow-up) 19 ± 5
Patients (age of onset at diagnosis) 7.9 ± 2.4
gender: male/female (%)
Controls 55/45
Patients 56/44
clinical manifestations N cases (%)
characteristics
Valvular lesion
Mitral valve lesion (MVL) 67 (54)
Combined valve lesion (CVL) 57 (46)
Carditis 79 (64)
Arthritis 71 (57)
Chorea 14 (11)
Skin rash 3 (2)
Subcutaneous nodules 2 (2)
Recurrence NA
laboratory findings at presentation
Elevated acute phase reactants (CRP/ESR) 98 (79)
Prolonged PR interval 68 (55)
N, number; N cases, number of cases; NA, not available; CRP, C-reactive protein; ESR, 
erythromycin sedimentation rate.
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for 10 min followed by 50 cycles at 95°C for 15 s and 60°C for 
1 min (annealing/extension). Fluorescence detection took place 
at 60°C. Non-template controls were included in each run. The 
genotype call rate was over 99%. Duplicate genotyping of 10% of 
samples selected at random was performed for quality control. 
Assays were performed using the StepOnePlus system, and the 
automated Sequence Detection Software (SDS) v2.3 was used for 
auto-calling (Applied Biosystems).
The MIF-794 repeat was genotyped by conventional PCR, 
and the product was separated by capillary electrophoresis 
(3500 Genetic Analyzer, Life Technologies, Carlsbad, CA, USA). 
Reactions were performed with 10 pmol of each primer: forward 
primer (FAM-5′-AAATCTCTGAGGACCTGGCC-3′) and 
reverse primer (5′-CACCGTGTATGGCCTCTCAT-3′) designed 
using Primer3.1 PCR products were detected by capillary elec-
trophoresis using the fluorescently labeled forward primer. 
Amplifications were carried out in a 10-μl reaction volume con-
taining 30-ng genomic DNA in 2× Go-Taq Master Mix includ-
ing MgCl2, 10× PCR buffer, dNTPs, and 10 units of Taq DNA 
polymerase (M7132, Promega, Madison, WI, USA). Samples 
were amplified using the Veriti thermal cycler (Life Technologies, 
Carlsbad, CA, USA). The cycling and amplification conditions 
were initial denaturation at 95°C for 2 min followed by 35 cycles 
with denaturation at 95°C for 15 s, annealing at 60°C for 15 s, and 
extension at 72°C for 30 s. Automated capillary electrophoresis 
on the 3500 Genetic Analyzer was performed for each sample 
following the manufacturer’s protocol, and the CATT alleles were 
identified using GeneMapper v4.1 software (Life Technologies).
statistical analysis
Statistical analyses were conducted using SPSS version 17 (IBM 
Statistics, Chicago, IL, USA). In addition, results were confirmed 
using a freely available online statistical tool, VassarStats.2 
Genotyping data were checked for any deviation from Hardy–
Weinberg equilibrium (HWE) using chi-squared contingency 
tables. Genotype and allele frequencies were determined by 
direct counting in patients and controls. Significant differences 
in the distribution of MIF promoter polymorphisms between 
cases and controls were tested using chi-squared contingency 
tables or Fisher’s exact test as appropriate. Linear regression was 
used to test for any association between the genetic variations 
and age of onset (the dependent variable was age of onset and 
allele frequencies were predictors). Odds ratios (ORs) and 95% 
confidence intervals (CIs) were calculated. A p-value <0.05 was 
considered statistically significant.
resUlTs
Patient characteristics
The demographic and baseline characteristics of the patients at 
disease presentation according to echocardiographic findings are 
presented in Table 1. Three hundred twenty-six Saudi Arabian 
individuals (202 controls and 124 patients) were genotyped for the 
1 http://primer3.ut.ee/
2 www.vassarstats.net
MIF-173 (rs755622) and MIF-794 (rs5844572) polymorphisms. 
RHD patients were 56% males and 44% females, and 67 patients 
(54%) had MVL and 57 patients (46%) had CVL. Carditis (64%) 
and arthritis (57%) were present in the majority of patients. Acute 
phase reactants were elevated in 79% of patients at presentation 
(Table 1).
Distribution of MiF Polymorphisms
The genotypes, allele frequencies, and allele carriage distribu-
tions are shown in Table 2. There were no deviations from the 
HWE in patients or controls for either MIF variant. The genotype 
and haplotype frequencies of MIF promoter polymorphisms 
in the control group were consistent with similar published 
studies from other countries; however, this is the first report of 
frequencies of these polymorphisms in a Saudi Arabian or Arab 
population. The allelic frequencies of the 173 polymorphism in 
healthy controls were similar to those reported in studies from 
Turkey, the Netherlands, and Caucasians from New Zealand 
(30–32), but different to those reported in a Mexican population 
(33). Similarly, distributions of the 5-, 6-, 7-, and 8-CATT alleles 
located at the 794 locus were comparable to those reported from 
Italy and Belgium (34), but different to Mexican and Japanese 
populations (33, 35).
relationship between MIF Polymorphisms 
and rhD
The MIF polymorphism genotype and allele frequencies were 
different in patients with RHD. There was a significant difference 
in the distribution of the MIF-173 genotype frequency between 
TaBle 2 | Distribution of MIF-173 polymorphism genotypes and allele frequencies in patients and controls.
MIF-173 control (N = 202) Patients (N = 124) χ2 df p-value Or (95% ci)
count Frequency count Frequency
genotype
GG 122 0.60 95 0.77 10.2 2 0.006
GC 64 0.32 26 0.21
CC 16 0.08 3 0.02
allele frequency
G 308 0.76 216 0.87 Ref.
C 96 0.24 32 0.13 11.5 1 0.0007 0.48 (0.31–0.74)
allele carriage
(GG + GC) vs. CC 186 0.92 121 0.98 4.2 1 0.04 3.5 (0.99–12.2)
(CC + GC) vs. GG 80 0.4 29 0.23 9.1 1 0.003 0.47 (0.28–0.77)
Significant findings are shown in bold; N, number.
TaBle 3 | Distribution of MIF-794 repeat genotypes and allele frequencies in patients and controls.
MIF-794[caTT] control (N = 202) Patients (N = 124) χ2 p-value Or (95% cis)
count Frequency count Frequency
genotype
5/5 19 0.09 3 0.02 5.96 0.02 0.24 (0.07–0.82)
5/6 64 0.32 35 0.28 0.4 0.5 0.9 (0.5–1.4)
5/7 7 0.03 3 0.02 0.3 0.6 0.7 (0.18–2.7)
5/8 4 0.02 0 0.00 2.5 0.1 0.98 (0.96–1)
6/6 82 0.41 69 0.56 7.0 0.008 1.8 (1.17–2.9)
6/7 18 0.09 10 0.08 0.07 0.8 0.9 (0.4–2)
6/8 6 0.03 1 0.01 – 0.3 –
7/7 2 0.01 2 0.02 – 0.6 –
7/8 0 0.00 0 0.00 – – –
8/8 0 0.00 1 0.01 – – –
X allele carriage
(5/5 + 5/X) vs. X/X 94 0.47 41 0.33 5.7 0.02 0.57 (0.36–0.9)
(X/X + 5/X) vs. 5/5 183 0.91 121 0.98 6.0 0.01 4.2 (1.2–14.5)
allele freq.
5 113 0.28 44 0.18 8.8 0.003 0.56 (0.38–0.82)
6 252 0.62 184 0.74 9.7 0.002 1.7 (1.2–2.5)
7 29 0.07 17 0.07 0.03 0.9 1 (0.51–1.8)
8 10 0.02 3 0.01 – 0.4 –
X allele freq. 291 0.82 204 0.72 8.8 0.003 1.8 (1.22–2.66)
Significant findings are shown in bold; N, number; X refers to 794 CATT alleles 6–8.
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patients and controls (χ2 = 10.2, p = 0.006; Table 2). MIF-173C 
allele frequencies were associated with a decrease in RHD risk 
(χ2 = 11.5, p = 0.0007, OR = 0.48, 95% CIs 0.31–0.74). Likewise, 
173C allele carriage (CC +  GC vs. GG) was associated with a 
decreased risk of developing RHD (χ2 = 9.1, p = 0.003, OR = 0.47, 
95% CIs 0.28–0.77).
The genotypic and allelic frequencies for the MIF-794 CATT5–8 
repeat variation in RHD and healthy subjects are shown in 
Table  3. On the one hand, the 794CATT5-allelic frequencies 
were significantly higher in the control group than RHD patients 
(χ2 = 8.8, p = 0.003, OR = 0.56, 95% CIs 0.38–0.82). On the other 
hand, 794 CATT6-allelic frequencies were associated with an 
increased risk of developing RHD (χ2 = 9.7, p = 0.002, OR = 1.7, 
95% CIs 1.2–2.5). Most evidence indicates that 794 CATT6–8 
repeats have higher transcriptional activity than 794 CATT5 
repeats; therefore, we grouped 794 CATT6–8 repeats and termed 
them the X allele. X-allele frequency was more common in RHD 
subjects than in healthy controls (χ2 = 8.8, p = 0.003, OR = 1.8, 
95% CIs 1.22–2.66).
MiF genotype Distribution and age of 
Disease Onset
In linear regression analysis, the age of onset was significantly 
greater for MIF-173C allele carriers than non-MIF-173C allele 
carriers in RHD patients (p = 0.001; Figure 1). The mean ages 
FigUre 1 | Mean of age at onset for 173c allele non-carriers (N = 94) 
and carriers (N = 28). The mean age at onset of non-C allele carriers and C 
allele carriers were 7.5 ± 2.4 and 9.2 ± 1.6, respectively. N, number.
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of onset of C-allele carriers and non-carriers were 9.2  ±  1.6 
and 7.5 ± 2.4, respectively. There was no significant association 
between the tetranucleotide variation and disease age of onset 
(data not shown).
DiscUssiOn
Accumulation of deleterious and disease-associated genetic vari-
ations in immune genes has been linked to autoimmune disease 
susceptibility (36). RHD is a multifactorial disorder involving 
multiple genetic and environmental factors. Although it remains 
a common autoimmune heart disease in children in developing 
countries, only a few studies from these regions have explored 
the influence of genetic variations in immune genes in RHD (37).
In this pilot case–control study, the impact of MIF functional 
variations was evaluated with respect to RHD susceptibility and 
severity in 326 Saudi Arabian individuals (202 controls and 124 
patients). We report that the pleiotropic inflammatory cytokine 
MIF exerts dual effects in RHD patients. The 173C allele was 
associated with reduced RHD risk and, interestingly, this geno-
type was associated with later disease onset. In contrast, the 794 
CATT6 allele was associated with increased RHD risk, but the 
794 CATT5 allele was associated with reduced RHD risk. Genetic 
variability in MIF may have a dual impact on the development of 
RHD in the Saudi Arabian population.
The pleiotropic roles of MIF and MIF alleles on the immu-
nopathogenesis of infectious and autoimmune diseases have 
been documented. For example, in SLE, MIF alleles associated 
with higher gene expression (173C and 794 extended alleles) are 
associated with a lower risk of SLE (38). However, in patients 
with established disease, lower expression alleles are associated 
with reduced end-stage organ involvement (28). Interestingly, the 
MIF-173C allele has been associated with a lower incidence of 
antinuclear antibody (ANA) development in SLE, supporting a 
protective role for MIF in SLE (17). On the other hand, a meta-
analysis has shown that 173 polymorphisms are a risk factor for 
inflammatory bowel disease; however, due to a lack of clinical 
details and original data, the effect of MIF polymorphisms on 
disease progression and severity could not be analyzed (39). 
Similarly, MIF-794 allele 7 has been shown to be a risk factor 
for the development of rheumatoid arthritis; however, 794 allele 
5 is correlated to reduced disease severity (33, 40). In another 
autoimmune disease, systemic sclerosis, the MIF-173 polymor-
phism was associated with the development of the diffuse and 
more severe form of the disease in a large meta-analysis (41). 
The role of MIF in different diseases is clearly highly cell- and 
disease-context dependent.
MIF polymorphisms and protein expression also have an 
impact on outcomes in patients with infectious diseases. In 
African and Indian studies, longer CATT repeats were associated 
with malarial complications, such as severe malarial anemia (27) 
and cerebral malaria (42), which are the main causes of death 
in these patients. Interestingly, the frequency of the shortest 
CATT-5 repeat was greatest in African populations, leading to 
the speculation that MIF low expression alleles may be protective 
against malaria, similar to the effect seen with sickle hemoglobin 
(HbS) genes (17).
To our knowledge, this is the first case–control study of the 
impact of MIF promoter variations on RHD risk. One Turkish 
study explored the influence of the 173 polymorphism on acute 
RF, the precursor of RHD, and reported that the polymorphism 
conferred increased risk (43). However, the authors did not 
report any clinical details on RHD in this cohort. Unfortunately, 
we could not examine the effect of MIF on RF since our patients 
were recruited from a tertiary cardiac center that only receives 
patients with established valvular disease. Nevertheless, it has 
been shown that MIF plays an important role in heart disease 
(44). In myocardial infarction (MI), myocardiocyte-secreted 
MIF exerts a protective effect when cardiac ischemia is brief by 
activating AMP-activated protein kinase (AMPK) and stress sup-
pression (44). AMPK phosphorylation promotes glucose uptake 
via glucose transporter-4 (GLUT4), thereby providing metabolic 
protection (45). However, in prolonged ischemia, MIF activates 
immune cells and increases inflammation, cardiac remodeling, 
and fibrosis by promoting matrix protein synthesis by myofi-
broblasts (45). In RHD, valvular damage is caused by recurrent 
rheumatic insults. In some patients, persistent inflammation 
leads to the formation of Aschoff bodies, which are granuloma-
tous lesions characterized by mononuclear cell and macrophage 
infiltrates in the myocardium and endocardium. Over the disease 
course, the valves become thickened and, eventually, stenosed. 
MIF’s role in these inflammatory foci has yet to be studied, but it 
is possible that, in the early stages of the disease, MIF might help 
to clear certain pathogens and apoptotic cells (46). In turn, this 
could help to protect cardiomyocytes and delay valvular damage. 
Conversely, recurrent rheumatic insults in the presence of MIF 
may increase inflammatory cell recruitment and promote proin-
flammatory mediators, thereby enhancing regional inflammation 
and damaging cardiac tissue.
Of particular note, the MIF-173C allele was associated with later 
disease onset as well as decreased risk of RHD. To our knowledge, 
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this is the first study to examine the effect of polymorphisms 
on the age of onset of RHD. These data suggest that MIF action 
may be age dependent; however, the results must be considered 
with caution since there are different definitions of “age of onset,” 
and advanced diagnostic echocardiography has influenced RHD 
burden data (47, 48). Several studies have shown that MIF is 
age dependent in other diseases: adults with a low-expressing 
MIF allele (CATT5) are at high risk of Gram-negative bacterial 
infections (49) and high-expressing MIF genotypes protect older 
patients from sepsis mortality (50). In animal models, the protec-
tive role of MIF during ischemic injury is abolished in senescent 
hearts, an effect correlated to impaired AMPK activation and 
low MIF expression levels (51). Interestingly, exogenous MIF 
can effectively rejuvenate stem cells isolated from age-induced 
senescent animals (52). Clearly, MIF variations influence disease 
severity and progression; therefore, future clinical studies need to 
collect and analyze data that includes disease stage and patient age.
Here, we report an association between MIF promoter 
variations and RHD. These findings require replication in larger, 
multi-ethnic studies to overcome some of the ethnic bias in our 
study, the retrospective analysis, and to provide sufficient power 
for robust subgroup analysis. Furthermore, we only analyzed 
two polymorphisms and not the entire MIF gene, and it would 
be useful to analyze other MIF polymorphisms and functional 
genetic variations in downstream signaling pathways to fully 
elucidate the function of this pathway in RHD. Finally, studies 
from Arab countries are scarce with respect to MIF variations in 
any infectious or autoimmune diseases, making ethnic compari-
sons difficult and only permitting comparisons with results from 
non-Arab populations.
In conclusion, MIF promoter variants may have an impact on 
RHD susceptibility, severity, and age of onset. Further prospec-
tive, multi-ethnic studies are required.
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